VibrantWellness

The Gut-Hormone Connection: How Beta-Glucuronidase Shapes Estrogen Metabolism and Patient Outcomes



By Dr. Susan Lovelle, MD

Published 11/6/2024

Table of Contents





Introduction

What if you could harness a hidden player in the gut that predictably influences your patients' response to hormone therapy? How would that impact them and your practice?

Recent studies point to beta-glucuronidase, an enzyme produced by certain gut bacteria, playing a pivotal role in hormone metabolism—particularly estrogen. We're just beginning to understand this enzyme's impact on hormone-related conditions like breast cancer, PCOS, and menopausal symptoms.

Understanding the interplay between gut health and hormone metabolism is crucial for healthcare providers, especially those managing patients on hormone replacement therapy (HRT). Addressing imbalances in gut bacteria and beta-glucuronidase activity may improve HRT's efficacy and alleviate persistent unwanted symptoms in patients.

In this guide, we will dive into the role of beta-glucuronidase, explore how an imbalance in gut bacteria known as dysbiosis affects its activity, and outline evidence-based strategies for testing and managing beta-glucuronidase levels. By the end, you'll have a clearer understanding of how to integrate gut health into a comprehensive approach to hormonal care, optimizing outcomes for your patients.

Beta-Glucuronidase and Its Role in Estrogen Metabolism

A critical component in understanding estrogen metabolism is the role of beta-glucuronidase, a gut bacterial enzyme that influences the recycling of estrogen. This enzyme is part of a broader bacterial gene network known as the **estrobolome**, which metabolizes estrogens and regulates their excretion from and reactivation in the body.

Estrogen metabolism begins in the liver, where estrogen is conjugated (bound for excretion) via a process known as **glucuronidation**. This process makes the hormone water-soluble, allowing it to be excreted via the kidneys and through bile into the intestines. However, once in the intestines, beta-glucuronidase—produced by specific gut bacteria within the estrobolome—deconjugates the estrogen, reactivating it and enabling its reabsorption into the bloodstream. This process is called **enterohepatic circulation**.

In this way, the estrobolome controls estrogen levels, determining the balance between reabsorption and excretion. While this reactivation can help maintain hormone balance under normal conditions, elevated beta-glucuronidase activity can lead to excessive estrogen reabsorption. A healthy estrobolome maintains a balance that supports optimal estrogen levels.

However, an overactive estrobolome, particularly if secondary to dysbiosis (an imbalance in gut microbiota) or the overgrowth of beta-glucuronidase-producing bacteria like Bacteroides and Clostridia, can lead to excessive estrogen reabsorption. This process contributes to estrogen dominance, a condition linked to hormone-driven disorders such as breast and endometrial cancers, endometriosis, and fibroids.

Beta-glucuronidase and Estrogen-Related Disorders

According to Sui et al. (2021), beta-glucuronidase reactivation of estrogen plays a significant role in the development of **gynecologic cancers and menopausal symptoms**. Elevated levels of this enzyme, particularly in dysbiotic guts, increase the circulation of free estrogen, which can bind to estrogen receptors and exacerbate hormone-driven conditions, particularly in postmenopausal women. Ervin et al. (2019) also emphasize the **dual nature** of beta-glucuronidase. While this enzyme is essential in regulating hormone levels, unchecked activity can result in excess estrogen reabsorption, increasing the risk for hormone-driven cancers.

The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer

Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens

Similarly, Shiwan Hu et al. (2023) highlight the importance of the estrobolome in **regulating estrogen levels** throughout a woman's life, from menstruation to menopause. Disruptions in estrobolome function, particularly through elevated beta-glucuronidase activity, are linked to increased risks of gynecological cancers, menopausal symptoms, and other estrogen-related disorders.

Now that you understand the importance of gut health and the estrobolome on estrogen metabolism, how does poor gut health affect your patient's hormones, and what can you do about it?

Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism

The Impact of Dysbiosis on Hormonal Health

In a healthy gut, beneficial bacteria such as Lactobacillus and Bifidobacterium keep beta-glucuronidase levels in check, ensuring a proper balance between estrogen excretion and reabsorption. Dysbiosis is an imbalance in gut microbiota in which key beneficial (commensal) species become overrun by less favorable and/or more inflammatory bacteria or other microorganisms. Opportunistic bacteria like Bacteroides and Clostridia, which preferentially produce beta-glucuronidase, can overgrow when dysbiosis occurs, leading to elevated enzyme levels and excessive estrogen recycling.

Altered estrogen levels are not the only consequence; of note, dysbiosis can also affect the metabolism of androgens like testosterone and dihydrotestosterone (DHT), which can exacerbate symptoms of androgen excess in conditions like PCOS.

Inflammation caused by chronic dysbiosis can seriously disrupt hormone regulation by interfering with the HPG axis. This critical system controls the production and regulation of sex hormones like estrogen, testosterone, and progesterone. This disruption occurs when harmful gut bacteria proliferate and release pro-inflammatory compounds such as lipopolysaccharides (LPS), which are endotoxins found in the outer membrane of Gram-negative bacteria. LPS can cross the gut barrier, especially when the barrier becomes "leaky" due to inflammation, and enter the bloodstream, triggering systemic inflammation.

Once in circulation, LPS can stimulate the immune system and disrupt normal signaling pathways in the HPG axis, which regulates hormone production through the ovaries and testes. Chronic inflammation driven by LPS interferes with the production and release of gonadotropin-releasing hormone (GnRH) in the hypothalamus. GnRH stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH), both essential for stimulating the gonads to produce sex hormones. Disruptions in this feedback loop can lead to imbalanced hormone production, including reduced levels of estrogen and testosterone.

Moreover, this inflammation can exacerbate the effects of beta-glucuronidase activity. In a dysbiotic gut, elevated beta-glucuronidase levels promote excessive estrogen reabsorption, contributing to estrogen dominance. When combined with LPS-induced inflammation, which already disrupts normal hormone signaling, the body's ability to regulate and balance hormone levels is further compromised. This duo can intensify symptoms of hormone imbalances such as irregular menstrual cycles, infertility, and mood disturbances.

In addition to hormone signaling disruption, chronic inflammation from LPS can impair the liver's capacity to detoxify hormones effectively, further compounding the issue of hormone dysregulation. The liver conjugates estrogen, as well as other hormones and toxins, for excretion. However, this detoxification process becomes less efficient when inflammation hinders liver function, allowing more estrogen to be reabsorbed via beta-glucuronidase activity. This combination creates a vicious cycle of estrogen reactivation, hormonal imbalance, and continued inflammation, making restoring normal hormone levels without addressing gut health and systemic inflammation increasingly difficult.

By managing dysbiosis and reducing systemic inflammation, healthcare providers can help mitigate the effects of beta-glucuronidase on hormone reabsorption, ultimately improving overall hormone regulation and patient outcomes.

Diagnostic Tools for Evaluating Beta-Glucuronidase and Hormonal Imbalances

Assessing gut health and estrogen metabolism is essential for effectively managing beta-glucuronidase activity and improving hormonal health. Healthcare providers can and should utilize specific diagnostic tools to identify imbalances and guide treatment.

Stool Testing for Microbiome Diversity, Dysbiosis, and Beta-Glucuronidase

Which specific tests will support your patient's hormonal balance?

The **Vibrant Wellness Gut Zoomer** is a comprehensive stool test that measures over 170 species of bacteria and gut pathogens along with gut microbiota diversity, dysbiosis markers, and beta-glucuronidase activity. In conjunction with information about digestive function, inflammation, and gut barrier strength, you'll have a solid starting point to determine the gut health of your patients.

Hormone Metabolism Testing

The Vibrant Wellness Urinary Hormones Panel offers insights into how estrogen is metabolized. Providers can assess the impact of gut dysbiosis on estrogen metabolism by measuring urinary levels of steroid hormones along with the downstream compounds resulting from metabolism (urinary hormone metabolites).

Elevated beta-glucuronidase levels often result in higher levels of proliferative estrogen metabolites such as 4-OH Estrone and 16A-OH Estrone and negatively skew important ratios such as 2-OH (E1 + E2)/16a-OH E1, which is believed to be an independent risk factor for breast cancer. With this information, you can develop targeted strategies.

Vibrant's Gut Zoomer Test

Vibrant's Urinary Hormones Panel

Adjusting Hormone Replacement Therapy (HRT) for Dysbiosis

For patients on hormone replacement therapy (HRT), dysbiosis can complicate treatment outcomes. As previously discussed, elevated beta-glucuronidase levels due to dysbiosis can cause excessive reabsorption of conjugated estrogen, leading to unpredictable hormone levels. This reabsorption may increase the risk of side effects such as breast tenderness, weight gain, and even thromboembolic events.

To mitigate these risks, providers should consider adjusting HRT dosage and addressing gut dysbiosis simultaneously:

1. **Lower the Estrogen Dose:** Reducing the estrogen component of HRT can help prevent estrogen dominance due to excessive reabsorption.
2. **Calcium-D-Glucarate:** This supplement inhibits beta-glucuronidase activity, reducing the enterohepatic recycling of estrogen and promoting its excretion.
3. **Probiotic Supplementation:** Introducing probiotics such as Lactobacillus rhamnosus and Bifidobacterium lactis can help restore gut balance and lower beta-glucuronidase activity.

Case Study: Improving Estrogen Dominance

Jessica, a 42-year-old lawyer with a history of irregular cycles and fibroids, struggled with persistent bloating, mood swings, and weight gain. **Gut Zoomer** testing revealed elevated beta-glucuronidase levels, suggesting excessive estrogen reabsorption. These elevated levels, confirmed with the **Urinary Hormones Test**, were compounded by prematurely low progesterone, resulting in estrogen dominance.

Dietary changes with targeted probiotics and supplementation, including calcium D-glucarate were instituted, her estrogen levels began to balance, and her symptoms improved within three months.

Clinical Strategies for Balancing Beta-Glucuronidase

To effectively manage beta-glucuronidase and support hormonal health, healthcare providers can implement several clinical strategies:

1. Dietary Interventions
A fiber-rich diet supports beneficial gut bacteria and helps lower beta-glucuronidase levels. Aim for 25-35 grams of fiber daily from whole grains, vegetables, and legumes. Additionally, incorporating anti-inflammatory foods like turmeric, ginger, and omega-3-rich fish helps reduce gut inflammation and supports a balanced microbiome.

2. Probiotic Therapy
Probiotics can significantly reduce beta-glucuronidase activity by promoting the growth of beneficial bacteria. Strains such as Lactobacillus rhamnosus and Bifidobacterium lactis have been shown to lower beta-glucuronidase production and improve estrogen detoxification.

3. Calcium-D-Glucarate
As a supplement, calcium-D-glucarate inhibits beta-glucuronidase and promotes the proper excretion of estrogen. It is particularly beneficial for patients with elevated beta-glucuronidase due to dysbiosis.

4. Liver Support
Liver-supportive supplements like milk thistle and curcumin help enhance the liver's ability to detoxify estrogen and reduce overall inflammation, supporting a healthier hormonal balance.

Case Study: Reducing PCOS Symptoms

Sara, a 28-year-old teacher with PCOS, presented with acne, hirsutism, and menstrual irregularities. Initial **Urinary Hormones Test** showed elevated testosterone, while her **Gut Zoomer** indicated high beta-glucuronidase and gut dysbiosis.

After modifying her diet to include more fiber, adding targeted probiotics, and supporting liver detoxification, Sara's symptoms began to stabilize. Her follow-up tests revealed lower beta-glucuronidase activity and improved hormone metabolism as she enjoyed more regular cycles.

Monitoring and Adjusting Treatment Plans

Once a treatment plan has been implemented, monitoring beta-glucuronidase levels and hormone metabolism is essential to ensure consistently effective interventions. Providers should re-test beta-glucuronidase levels after three to four months using tools like the **Vibrant Wellness Gut Zoomer** and evaluate estrogen metabolite profiles using the **Urinary Hormones Test**. If beta-glucuronidase levels remain elevated, consider adjusting dietary recommendations, probiotics, or supplements.

Additionally, monitoring patient-reported symptoms—such as improvements in PMS, menopausal symptoms, and overall mood—provides valuable insight into the efficacy of the treatment plan. A deeper dive into adrenal function or thyroid health may be appropriate if symptoms persist.

The Bottom Line

Balancing beta-glucuronidase activity is essential for managing estrogen metabolism and improving hormonal health. By addressing gut health through diet, probiotics, and supplements like calcium-D-glucarate, providers can help patients achieve better outcomes in conditions like estrogen dominance, PCOS, and hormone-sensitive cancers. Regular monitoring through stool and hormone testing ensures that treatment protocols can be adjusted as needed, offering a comprehensive approach to hormonal balance and well-being.

In summary, beta-glucuronidase and the estrobolome profoundly impact estrogen metabolism. While these processes are essential for maintaining hormonal balance, elevated enzyme activity can lead to excessive estrogen reabsorption and contribute to hormone-related diseases. For savvy healthcare providers, addressing gut dysbiosis and modulating beta-glucuronidase activity can help manage estrogen-related conditions and improve patient outcomes.

About the Author

Dr. Susan Lovelle, a former award-winning plastic surgeon, is the Founder of **Balanced Performance**, offering all-in-one lifestyle health solutions for busy executives and the innovative companies they lead. She specializes in boosting their energy, optimizing weight, and balancing hormones to unlock peak performance in every aspect of life. Dr. Susan has been featured on The Doctors, the docu-series Exhausted, Lifetime TV, Forbes, DWEN, and Good Morning Washington. Her book, Thrive! The Five-Week Guide to Mastering Your Energy At Any Age is available on Amazon.

Scan to check out the Balanced Performance website

References

1. The Role of Gut Microbial B-Glucuronidase in Estrogen Reactivation and Breast Cancer. Sui Y, Wu J, Chen J. Frontiers in Cell and Developmental Biology. 2021;9:631552.
2. Gut Microbial B-Glucuronidases Reactivate Estrogens as Components of the Estrobolome That Reactivate Estrogens. Ervin SM, Li H, Lim L, et al. The Journal of Biological Chemistry. 2019;294(49):18586-18599.
3. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Shiwan Hu, Qiyou Ding, Wei Zhang, Mengjiao Kang, Jing Ma & Linhua Zhao Article: 2236749 | Received 01 May 2023, Accepted 10 Jul 2023, Published online: 09 Aug 2023
4. Microbiome, sex hormones, and cardiovascular risk: a contribution to gender difference Silvia Maffei 1, Ilaria Citti 2, Letizia Guiducci 3 1 Department of Cardiovascular and Gynecological Endocrinology CNR-Regione Toscana 'G. Monasterio Foundation', Pisa, Italy; 2 Institute of Clinical Physiology, CNR, Pisa, Italy; 3 Laboratory of Biochemistry and Molecular Biology, Institute of Clinical Physiology, CNR, Pisa, Italy
5. Serum Level of Sex Steroid Hormone Is Associated With Diversity and Profiles of Human Gut Microbiome. Shin JH, Park YH, Sim M, et al. Research in Microbiology. 2019 Jun - Aug;170(4-5):192-201. doi:10.1016/
6. Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity-a Systematic Review. d'Afflitto M, Upadhyaya A, Green A, Peiris M. Journal of Clinical Gastroenterology. 2022 May-Jun 01;56(5):384-392.
7. The gut microbiota is a major regulator of androgen metabolism in intestinal contents Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E1182-E1192. Hannah Colldén, Andreas Landin, Ville Wallenius, Erik Elebring, Lars Fändriks, Maria E Nilsson, Henrik Ryberg, Matti Poutanen, Klara Sjögren, Liesbeth Vandenput, Claes Ohlsson
8. From Gut to Hormones: Unraveling the Role of Gut Microbiota in (Phyto)Estrogen Modulation in Health and Disease. Kumari N, Kumari R, Dua A, et al.
9. Gut Microbiota Is Involved in Male Reproductive Function: A Review. Lv S, Huang J, Luo Y, et al. Frontiers in Microbiology. 2024;15:1371667. Molecular Nutrition & Food Research. 2024;68(6):e2300688.
10. From the Vibrant Urine Hormones Interpretive Guide: Urinary estrogen metabolites in women at high risk for breast cancer. Im A, Vogel VG, Ahrendt G, Lloyd S, Ragin C, Garte S, Taioli E. Carcinogenesis. 2009 Sep;30(9):1532-5.

Regulatory Statement:

The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions. This test has been laboratory developed and its performance characteristics determined by Vibrant America LLC and Vibrant Genomics, a CLIA-certified and CAP-accredited laboratory performing the test. The lab tests referenced have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.